Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 18/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21860422 | 0.78 | FGFR4 (0.49) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL15434021 | 0.77 | FGFR1 (0.74) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL19363674 | 0.75 | FGFR4 (0.76) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL19363708 | 0.75 | FGFR1 (0.51) | FGFR4FGFR1FGFR2FGFR3EGFR | |
| SCHEMBL23653226 | 0.73 | EGFR (0.51) | FGFR4FGFR1FGFR2FGFR3EGFR | |
| SCHEMBL19363809 | 0.73 | FGFR4 (0.41) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL24225216 | 0.73 | FGFR4 (0.49) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL19068972 | 0.72 | FGFR4 (0.74) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL19792901 | 0.71 | FGFR4 (0.59) | FGFR4 | |
| SCHEMBL16071593 | 0.71 | FGFR4 (0.79) | FGFR4FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | CELGENE CAR LLC (BM) | 2020-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | PDXK, DCK, DTYMK | FGFR4 1220/4885FGFR1 1156/4885FGFR2 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.